• HOME
• Maternal Child
  • Maternal Child Home
  • Breastfeeding
  • Family Planning
  • Child Health Notes
  • OB/GYN CCC Corner
  • Perinatologist Corner
  • Pregnancy
• Female Health Systems
  • FHS Home Page
  • Access to Care
  • ACOG/IHS Course
  • Advanced Practice Nurses & PA(s)
  • APN/PA(s) Links
  • Conferences
  • Cultural Appropriateness
  • Discussion Groups
  • Evidence Based Practice
  • Forms
  • Helpful Links
  • Job Opportunities
  • Meeting Lecture Notes
  • Newsletters and Journals
  • Patient Education
  • Primary Care Discussion Forum
  • Programs, Databases and Resources
  • Training
• Women's Health
  • Women's Health Home Page
  • Cancer
  • Cardiovascular Disease
  • Diabetes
  • Mature Women
  • Mental Health
  • Sexually Transmitted Infections
  • Substance Abuse
• Violence Against Native Women
  • VANW Home Page
  • Clinical Tools
  • Community Action
  • Current Events
  • Legislative Action
  • Other Links
  • Patient Education
  • Policies and Procedures
  • Provider Education
  • Public Health
  • Resources
  • Sexual Assault

• Maternal Child Topics
  • Maternal Child Home
  • Breastfeeding
  • Family Planning
  • Child Health Notes
  • OB/GYN CCC Corner
  • Perinatologist Corner
  • Pregnancy

Maternal Child

Perinatologist Corner - C.E.U/C.M.E. Modules

HIV Infection in Pregnancy

Sponsored by The Indian Health Service Clinical Support Center

4. Read the material on zidovudine

Prevention of vertical transmission of H.I.V. from mother to infant is the major goal of this protocol. In 1994 the 076 study clearly demonstrated that zidovudine (Z.D.V.) treatment of the mother during pregnancy and in labor, and treatment of the infant in the neonatal period, was able to reduce the transmission rate from 25% to 8%. This protocol should be made available to all known H.I.V.-infected patients, regardless of viral load, CD4+ counts, or other drug therapy:

Antepartum: Oral administration of 100 mg zidovudine 5 times daily, initiated at 14-34 weeks gestation and continued throughout the pregnancy.

Intrapartum: Intravenous administration of Z.D.V. in a 1-hour initial dose of 2 mg/kg, followed by a continuous infusion of 1 mg/kg/hr until delivery. (If planned cesarean, Z.D.V. should be begun 3 hours prior to surgery.)

Postpartum: Oral administration of ZDV syrup 2 mg/kg q6h to the newborn for the first 6 weeks of life beginning 8-12 h after birth. (If unable to take p.o., give Z.D.V. 1.5 mg/kg I.V. q6h.)

3. Background ‹ Previous | Next › 5. Other antiretrovirals

Return to top of page